Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

This phase II trial compares the effect of relugolix to leuprolide on cardiac function and performance in patients with prostate cancer. Androgen deprivation therapy (ADT) has been a key component for the treatment of advanced prostate cancer for decades. The term androgen deprivation therapy means lowering a man's testosterone. Long-term studies show that ADT may contribute to a detriment to cardiac health and predisposes men to developing cardiac diseases. Recent studies suggest that men taking relugolix for treatment of prostate cancer may have a lower risk of developing cardiovascular prob

Trial Details

NCT ID

NCT06330805

Phase

PHASE2

Sponsor

Ohio State University Comprehensive Cancer Center

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Biospecimen Collection
Contrast Agent
Leuprolide
Magnetic Resonance Imaging
Physical Performance Testing
Relugolix

Locations (sample)

Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

Pathologically proven diagnosis of adenocarcinoma of the prostate within 270 days prior to registration.
Unfavorable intermediate risk prostate cancer, defined as having ALL the following bulleted criteria:
Has at least one intermediate risk factor (IRF):
Prostate-specific antigen (PSA) 10-20 ng/mL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →